Office: 206 Pavilion
Personal Website: www.cbligand.org/xielab www.CBLigand.org/CCGS www.CDARcenter.org
Xiang-Qun (Sean) Xie received his Pharmacy MD degree in 1982 from the Second Military Medical University in Shanghai China; his Ph.D. in Medicinal Chemistry from the School of Pharmacy, University of Connecticut, 1993; and followed by Biophysics Post-doctoral training at MIT Francis Bitter National Magnet Laboratory/UCONN. In addition, he received an Executive MBA degree in 2003. In 2011, he also received the Shared Leadership Cohort Development Experience Workshop Training by JPorcari & Associates, LLC.
Now, Dr Xie is a Professor of Pharmaceutical Sciences/Drug Discovery Institute and Associate Dean for Research Innovation at School of Pharmacy. He serves as a member of the United States Food and Drug Administration’s SCIENCE Board (the FDA’s highest advisory committee), and a charter member of the NIH BPNS Study Section. He is a recipient of 2014 AAPS Outstanding Research Achievement Award (the most prestigious award in pharmaceutical sciences). Sean Xie is Principal Investigator (PI) of an integrated research lab of CompuCore, BioCore and ChemCore (www.CBLigand.org/XieLab), Founding Director of Computational Chemical Genomics Screening (CCGS) Center (www.CBLigand.org/CCGS), and Director/PI of NIH funded National Center of Excellence for Computational Chemogenomics Drug Abuse Research (www.CDARCenter.org). He also holds joint faculty positions at the Department of Computational Biology and Department of Structural Biology, and Pitt Cancer Institute MT/DD Program. He serves as an oversea expert for the Chinese Natural Science Foundation, ad hoc reviewer for Netherlands Organization for Scientific Research (NWO) Council for Chemical Sciences (CW), MCMB Foundation for MRC United Kingdom, and the Wellcome Trust Fund, Sir Henry Wellcome Fellowship, London, UK. He is an Associate Editor for AAPS Journal, an Editorial Board of American Journal of Molecular Biology, and Associate Editor and Editorial Board of BMC Pharmacology and Toxicology. He also holds/held honorary professorship in top institutes and colleges of pharmacy in China, including Chinese Academy of Medical Sciences & Peking Union Medical College; Stem Cell Medical Center, CAMS Tianjin Institute of Hematology; Fudan University; Shanghai Jiaotong University and Zhejiang University. Dr. Xie was co-PI/core Director of the NIH funded Pittsburgh Center for Chemical Methodologies & Library Development (UPCMLD) and NCI/SAIC funded University of Pittsburgh Center for Diversity Chemistry (UP-CDC). He was co-PI of the Pittsburgh Molecular Library Screening Center (PMLSC) which was funded by the NIH Roadmap Initiative.
Before he joined Pitt, he was a Founding Director of Pharmacoinformatics Research Center in the College of Pharmacy at University of Houston Texas. He held several joint faculty positions at the Institute for Molecular Design (MDL), Texas Learning Computing Center (TLCC), and the Keck Center for Computational & Structural Biology, served as an Advisory Committee Member for the NIH Pharmacoinformatics Training Program at Houston Gulf Coast Consortium (GCC), and was a Director of the Chemistry Coordinating Unit for GCC-Chemical Genomics Screening Center. Prior to UH, Dr. Xie was a Director of the IMS NMR Lab and a joint faculty of the School of Pharmacy at the University of Connecticut for over 10 years, where he received multiple NIH grants and pharma support, including Pfizer, Boston Scientific companies, etc. He was an invited International Assessment Panelist for Fudan University College of Pharmacy, a member of the Board of Directors of the Chinese Association of Professionals in Science and Technology (CAPST), and a Chair of the CAPST-Biomedical & Pharmaceutical Society. He was keynote speaker and session chair/organizing committee for several international medicinal chemistry and drug design conferences/meetings.